All In Biotech

Drug Trial Radar · NCT03474029

Assessment of the Safety, Tolerability, and Effectiveness of Rifapentine Given Daily for LTBI

Six Weeks of Daily Rifapentine vs. a Comparator Arm of 12-16 Week Rifamycin-based Treatment of Latent M. Tuberculosis Infection: Assessment of Safety, Tolerability and Effectiveness

Last checked: Nov 19, 2026Latest source record: May 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 3,400 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

3,400

Planned (sponsor's estimate)

Start

Aug 1, 2019

Primary completion

Dec 31, 2029

Study completion Dec 31, 2029

Sponsor

Sponsor type
Federal agency
First posted
Mar 22, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is conducted to compare the safety and effectiveness of a novel short 6-week regimen of daily rifapentine (6wP, experimental arm) with a comparator arm of 12-16 weeks of rifamycin-based treatment (standard of care, control arm) of latent M. tuberculosis infection (LTBI). This trial is conducted among persons who are at increased risk of progression to tuberculosis (TB) and require treatment of LTBI. The study will be conducted in low, medium and high TB incidence settings that have treatment of LTBI as their standard of care and offer 12-16 week rifamycin-based therapy as standard of care. The hypothesis of this study is that the safety and effectiveness of the experimental treatment (6wP arm) is non-inferior to a comparator arm of 12-16 weeks of rifamycin-based treatment of LTBI (control arm). Participants are enrolled and randomly assigned to one of the two study arms: experimental 6wP or control. The comparator (control) arm's treatment regimens include 12 weeks of once-weekly isoniazid (INH) and rifapentine (3HP), 12 weeks of daily INH and rifampin (3HR), and 16 weeks of daily rifampin (4R). A total of 560 participants per arm (1,120 total) for the evaluation of safety and 1,700 participants per arm (3,400 total) for the evaluation of effectiveness will be enrolled, given treatment as per randomization assignment, and followed for 24 months from the date of enrollment. After completion of data collection, statistical analyses will be conducted to compare proportions of drug discontinuation due to adverse drug reaction (ADR) and proportions of newly diagnosed tuberculosis between 6wP and control arm.

Conditions

  • Latent Tuberculosis

Interventions

  • Rifapentine daily for 6 weeksDrug

    600 mg of Rifapentine (RPT) given once daily (o.d., omni die) for 6 weeks (6wP).

  • Rifapentine and Isoniazid weekly for 12 weeksDrug

    Rifapentine (RPT) 900 mg and isoniazid (INH) 900 mg given once-weekly for 12 weeks (3HP).\* \*Dose adjustments based on patient's weight will be made according to ATS/CDC/IDSA guidelines. RPT 900 mg once-weekly for persons weighing \> 50 kg. For persons weighing \< 50 kg, the following doses will be given: weight \> 25-32 kg - RPT 600 mg; weight \> 32-50 kg - RPT 750 mg; + INH 15 mg/kg (round up to nearest 50 or 100 mg; 900 mg max).

  • Rifampin and Isoniazid daily for 12 weeksDrug

    Rifampin (RIF) 600 mg and Isoniazid (INH) 300 mg given once-daily for 12 weeks (3HR)\*. \*Dose adjustments based on patient's weight will be made according to ATS/CDC/IDSA guidelines. RIF 600 mg daily for persons weighing \> 50 kg. For persons weighing \< 50 kg, give 10 mg/kg daily; round up to nearest 50 or 100 mg; + INH 5 mg/kg daily (rounded up to nearest 50 or 100 mg; 300 mg max).

  • Rifampin daily for 16 weeksDrug

    Rifampin (RIF) 600 mg given once-daily for 16 weeks (4R).\* \*Dose adjustments based on patient's weight will be made according to ATS/CDC/IDSA guidelines. RIF 600 mg daily for persons weighing \> 50 kg. For persons weighing \< 50 kg, 10 mg/kg daily; round up to nearest 50 or 100 mg.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Treatment discontinuation due to adverse drug reactionTime frame: from the date of enrollment to the date of scheduled completion of assigned treatment
  2. Culture-confirmed tuberculosis (TB) in participants 18 years old and older and culture-confirmed or clinical TB in participants less then 18 years old.Time frame: within 24 months from the date of enrollment

Locations

21 sites in 8 countries. Site status is shown where the registry gives one.

  • Denver Health and Hospital Authority

    Denver, Colorado · Recruiting

  • George Washington University

    Washington D.C., District of Columbia · Recruiting

  • Washington DC VA Medical Center

    Washington D.C., District of Columbia · Recruiting

  • New York Harbor Healthcare System

    Manhattan, New York · Recruiting

  • New York City Bureau of TB Control

    New York, New York · Recruiting

  • San Antonio VA

    San Antonio, Texas · Active not recruiting

  • Seattle King County Health Department

    Seattle, Washington · Recruiting

  • Liverpool Hospital

    Sydney, Australia · Recruiting

  • Paramatta Chest

    Sydney, Australia · Recruiting

  • Royal Prince Alfred Hospital

    Sydney, Australia · Recruiting

  • National Referral University Hospital for Pneumo-physiology

    Cotonou, Benin · Active not recruiting

  • Calgary TB Clinic

    Calgary, Alberta, Canada · Recruiting

  • Edmonton TB Clinic

    Edmonton, Alberta, Canada · Recruiting

  • British Columbia Centre for Disease Control

    Vancouver, British Columbia, Canada · Recruiting

  • Toronto Western Hospital

    Toronto, Ontario, Canada · Recruiting

  • McGill University Health Centre

    Montreal, Quebec, Canada · Recruiting

  • Les Centres Gheskio (INLR) CRS

    Port-au-Prince, Haiti · Recruiting

  • Desmond Tutu TB Center

    Stellenbosch, South Africa · Not yet recruiting

  • Joint Clinical Research Centre/ Makerere Univ Med Sch

    Kampala, Uganda · Recruiting

  • Ho Chin Minh City-District 6 TB Unit

    Ho Chi Minh City, Vietnam · Recruiting

  • Ho Chin Minh City-Phoi Viet Resportory Centre

    Ho Chi Minh City, Vietnam · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.